Skip to main content
. Author manuscript; available in PMC: 2019 Nov 1.
Published in final edited form as: J Rheumatol. 2018 Oct 1;45(11):1572–1576. doi: 10.3899/jrheum.171362

Table 1.

Baseline study population characteristics (N = 265).

Characteristic Mean ± SD or n (%)
Age at time of high-resolution computed tomography (HRCT), years 50 ± 12
Sex, woman 216 (82)
Body mass index, kg/m2 29 ± 6
Ethnicity, white 192 (73)
Smoker, current or former 97 (37)
Alcohol, current 96 (46)
Proton pump inhibitor use, current 171 (65)
SSc disease subtype
 Diffuse cutaneous 129 (49)
 Limited cutaneous 131 (49)
 Sine scleroderma 5 (2)
Years since first non-Raynaud SSc symptom to HRCT date 6 ± 11
Systemic sclerosis specific antibodies, positive
 Anti-topoisomerase I (Scl-70) 78 (30)
 Anticentromere (ACA) 48 (18)
 Anti RNA polymerase III 59 (23)
Modified Rodnan skin score 13 (11)
Radiographic interstitial lung disease present 188 (71)
Forced vital capacity (FVC) % predicted 76 (18)
Diffusing capacity for carbon monoxide (DLCO) % predicted 60 (20)